Morgan Stanley analyst Maxwell Skor downgraded Insmed (INSM) to Equal Weight from Overweight with a price target of $126, up from $112. The approval of Brinsupri came with a “clean” label and the company’s launch preparations bring confidence in the initial launch trajectory, the analyst tells investors in a research note. However, the firm believes Insmed’s current valuation largely captures the drug’s near-term opportunity. It cites valuation for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Brensocatib Approval Boosts Market Potential and Stock Valuation
- Insmed’s BRINSUPRI Approval and Strategic Pricing Justify Buy Rating and Increased Price Target
- Insmed price target raised to $140 from $130 at Wells Fargo
- Insmed price target raised to $138 from $120 at RBC Capital
- Brinsupri approval sets stage for next leg of Insmed growth, says BofA